http://www.sanofi-synthelabous.com
Sanofi is a French multi-national health care corporation dedicated to developing novel and innovative therapeutic agents for a wide range of clinical disorders. Xaliproden is an original Sanofi compound which exhibits neurotrophic and neuroprotective effects. It is being developed primarily as a potential treatment for ALS. Xaliproden is a nonpeptide compound that possesses neurotrophin-like activity. The compound reduces the histological (tissue), neurochemical and functional deficiencies produced in widely divergent models of experimental neurodegeneration. The ability of Xaliproden to increase the innervation of human muscle cells by spinal cord explants and to prolong the survival of mice suffering from progressive motor neuronopathy suggests the compound might be an effective therapy for the treatment of ALS. Even though the mechanism by which Xaliproden produces its neurotrophic and neuroprotective effects is not fully understood, it is thought to be related to the compound's ability to mimic the activity or stimulate the biosynthesis of a number of neurotrophins (such as NGF and BDNF) originating within the body.
RioTech is a spin-out company which is developing novel therapeutics from intellectual property around Hepatitis C virus infection. The founders are Professor Howard Thomas, Dr Mark Thursz, Dr Peter Karayiannis and Professor Graham Foster (now based at Queen Mary & Westfield College) from Imperial College and Professor Adrian Hill from Oxford University. RioTech was seed funded with £250,000 from the Imperial based University Challenge Seed Fund in 2003.
Biotron Limited (Biotron) is engaged in the funding and management of intermediate and early applied biotechnology research and development projects. During the fiscal year ended June 30, 2007 (fiscal 2007), the Company completed the Phase I human clinical trial of BIT225. Biotron’s BIT225 specifically targets Human Immunodeficiency Virus (HIV) in the viral reservoirs immune cells where the virus hides for long periods when the patient otherwise seems to be carrying negligible viral loads. (Source: ARS)
Plantigen Inc. is a discovery company focused on the identification and development of plant- derived biopharmaceuticals for the prevention and treatment of human disease. The company is a spin-off of the Lawson Health Research Institute, the research arm of the founding hospital in London, Ontario, Canada. Plantigen is developing products using genetically enhanced plants - ORAmmune* and PHYTOkines* to combat immune system disorders. These products are in their pre-clinical stage of development.
http://www.protoxtherapeutics.com
Protox Therapeutics Inc. (Protox) is a biopharmaceutical company focused on the research, development and commercialization of receptor-targeted fusion proteins. These fusion proteins specifically deliver potent payloads derived from engineered bacterial toxins or fully human Bcl-2 derived proteins to target cancer and other diseased cells. Protox is advancing a pipeline of discovery and clinical-stage product candidates developed from three complementary technology platforms: PORxin, INxin and HUMxin. The Company’s lead drugs in clinical development include the PORxin candidate, PRX302, for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH), commonly known as enlarged prostate, and the INxin candidate, PRX321, for primary brain cancer and other solid tumours. HUMxin, a next-generation platform technology, is a program being developed in collaboration with the United States National Institutes of Health. (Source: ARS)
EmerGen is a privately held biopharmaceutical company focused on the discovery and development of novel therapeutics and molecular diagnostics for diseases that predominantly affect women. Through the application of clinical genetics and reproductive genomics, EmerGen is identifying the fundamental causes of diseases that affect women and developing new therapeutic approaches to treat or prevent such diseases. The company is also applying its expertise in the area of reproductive biology to discover novel drug targets and disease pathways by investigating reproductive development processes. An understanding of these events will offer unique insights into cancer, immunosuppression, hypertension, and other major health problems. EmerGen intends to enter into a broad range of alliances to leverage its resources and accelerate development of products from discoveries in these areas. The company is based in Salt Lake City, Utah.
Biovation Limited is a private UK-based biopharmaceutical company specialising in antibody and protein engineering technology. The Company's proprietary de-immunization technology is designed to prevent adverse immunological reactions in patients which can limit the therapeutic potential of monoclonal antibodies and other proteins.
ACCESS Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and marketing novel therapeutics for cancer and related conditions. ACCESS has built a portfolio of proprietary anti-cancer product candidates through the in-licensing and acquiring of clinical-stage product candidates from emerging biotechnology companies.
Diabetogen Biosciences Inc. is a privately-held biotechnology company developing therapies for the prevention and treatment of autoimmune diseases, with an initial focus on the area of Type 1 (Insulin-Dependent) Diabetes. Founded in 2000, the company is developing a portfolio of products that will not only reverse the incidence of Type 1 Diabetes, but will also prevent the onset of the disease in susceptible individuals. Currently, three programs are underway, with three compounds targeted to be in human clinical trials for diabetes by the end of 2004. Additional molecules are continually being evaluated for consideration in new research programs. Those compounds that are shown to be effective in Type 1 Diabetes will be evaluated for their use in other autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. The company is seeking strategic alliances which will accelerate the development of its research programs.
Innodia is a privately held biopharmaceutical company with the mission of developing and bringing new drugs to the market for the treatment of type 2 diabetes and underlying diseases. Founded in 2002, Innodia had already raised US$10 million (CDN$14 million) in a Series A financing by the second quarter of 2003. In the fourth quarter of 2004, the Company secured a US$10 million (CDN$13 million) loan through the BioLevier program of Investissement Québec. In April 2006, Innodia announces the successful completion of a US$8 million (CDN$10 million) round of financing in the form of convertible debentures. The debentures will be converted into preferred shares at the next financing round. Innodia's current shareholders are listed below.
EvoGenix Limited is engaged in utilizing platform technologies to develop proteins, particularly antibodies, as therapeutic agents. The Company is focused on building biopharmaceuticals to meet the need in international pharmaceutical markets for treatment of diseases, such as cancer. The two parts of the EvoGenix technology platform, Superhumanisation and EvoGene protein optimization, can work separately or together to overcome the barriers for antibody development. The Company's products include EGX-010 for osteoporosis, bone cancer, Paget's disease, steroid therapy and arthritis; EGX-220, which targets high potency in stopping virus growth specifically for use in elderly patients; EGX-150, which is an anti-cancer antibody; EGX-130, which is a humanized and optimized antibody based on a mouse antibody used to treat primary liver cancer patients in China, and EGX-140, which is an anti-leukemia antibody under evaluation. EvoGenix operates in Australia and the United States. (Source: ARS)
Lorantis is pursuing immunology drug discovery and development through a unique molecular mechanism, Notch, that can be targeted to enhance or suppress antigen-specific immune responses. The company has two broad platforms to generate multiple products in areas of high unmet medical need. Antigen-specific immune suppressors are being developed for the treatment of allergy, asthma, autoimmune diseases and transplant rejection. By enhancing the immune response, Lorantis is addressing cancer and infectious diseases. The company has received venture backing from Apax Partners, Abingworth Management, Schroder Ventures Life Sciences, JP Morgan Partners, Quester, The Wellcome Trust and Northern Venture Managers.
Viron Therapeutics is a clinical stage biopharmaceutical company developing a completely new class of anti-inflammatory therapeutics to treat and prevent human inflammatory disorders. Viron's novel approach to drug development is based on the use of viral proteins as a source of therapeutic products. By harnessing the evolutionary power of viruses to withstand the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. The Company's lead compound, VT-111, is currently in a Phase II clinical trial for the treatment of vascular inflammation in patients with Acute Coronary Syndromes and will soon submit an IND for its second indication, the prevention of chronic organ rejection in transplant patients. Viron's pipeline of additional compounds in preclinical development, combined with a robust discovery program, strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory based diseases.
Montigen will discover and develop novel promising compounds for license or co-development with select pharmaceutical and biotechnology partners. The company will also utilize its proprietary technology in partnership with select partners. Our primary therapeutic focus is oncology. Montigen is keenly interested in discussing opportunities for potential strategic alliances with pharmaceutical and biotechnology companies to assist in the development and commercialization of our lead candidates.
Xcyte Therapies, Inc. is a biotechnology company developing a new class of therapeutic products designed to enhance the body's natural immune responses to treat cancer, infectious diseases and other medical conditions associated with weakened immune systems. Xcyte derives its therapeutic products from a patient's own T cells, which are cells of the immune system that orchestrate immune responses and can detect and eliminate cancer cells and infected cells in the body. Xcyte uses its patented and proprietary Xcellerate(TM) Technology to generate activated T cells, called Xcellerated T Cells(TM), from blood that is collected from the patient. Activated T cells are T cells that have been stimulated to carry out immune functions. The Xcellerate(TM) Technology is designed to rapidly activate and expand the number of the patient's T cells outside of the body. Xcyte is currently conducting clinical trials of Xcellerated T Cells(TM) in patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Xcyte(TM), Xcyte Therapies(TM), Xcellerate(TM) and Xcellerated T Cells(TM) are trademarks of Xcyte Therapies, Inc.
INNOVIVE Pharmaceuticals is a biopharmaceutical company headquartered in midtown Manhattan. Our mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. INNOVIVE is grounded in scientific and technical excellence. We are committed to creating value for shareholders, employees, caregivers and patients who use our products.
BioXell S.p.A is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of novel therapies for various medical needs. It is active in related therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male infertility), inflammation (sepsis, inflammatory bowel disease, post-surgical adhesions), pain and other therapeutic areas (secondary hyperparathyroidism and osteoporosis). The Company is headquartered in Milan, Italy.
PainCeptor Pharma is a pharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain. PainCeptor's therapeutic programs are concentrated on some of the most promising, novel, yet scientifically validated therapeutic targets within the PNS (peripheral nervous system). By focusing on modulating target receptors in the PNS, PainCeptor expects to enhance the efficacy and avoid the many detrimental side effects associated with today's pain drugs which act primarily in the CNS (central nervous system). PainCeptor's development pipeline includes two lead antagonist programs, targeting NGF/p75-TrkA and ASIC1a, and a third antagonist program targeting ASIC3.
Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company focused on the development of drugs for neurological disorders, metabolism and cancer. The drugs target acute indications of brain injury, such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, psychiatric symptoms of stroke, as well as chronic conditions, such as Parkinson’s and Alzheimer’s diseases. Neuren has four candidates, such as Glypromate, Motiva and NNZ-2566 in clinical development to treat four different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. The Company has operations in New Zealand and the United States. The Company acquired Hamilton Pharmaceuticals Inc. on October 15, 2007. (Source: ARS)
PharmaGap Inc. is a development stage company, principally engaged in drug development and out-licensing of drug compounds. It is a biotechnology company with the main focus on designing and developing therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). Using its drug development platform, the Company is developing a pipeline of compounds targeting PKC. PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes. As of December 31, 2007, the Company’s lead drug compound, PhGa1, was in the pre-clinical testing stage, and had shown in vitro and in vivo efficacy in selected cancer types. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory